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Abstract
The ubiquitin-like protein ISG15 (interferon-stimulated gene of 15 kDa) is strongly induced by type I interferons and displays
antiviral activity. As other ubiquitin-like proteins (Ubls), ISG15 is post-translationally conjugated to substrate proteins by an
isopeptide bond between the C-terminal glycine of ISG15 and the side chains of lysine residues in the substrates
(ISGylation). ISG15 consists of two ubiquitin-like domains that are separated by a hinge region. In many orthologs, this
region contains a single highly reactive cysteine residue. Several hundred potential substrates for ISGylation have been
identified but only a few of them have been rigorously verified. In order to investigate the modification of several ISG15
substrates, we have purified ISG15 conjugates from cell extracts by metal-chelate affinity purification and
immunoprecipitations. We found that the levels of proteins modified by human ISG15 can be decreased by the addition
of reducing agents. With the help of thiol blocking reagents, a mutational analysis and miRNA mediated knock-down of
ISG15 expression, we revealed that this modification occurs in living cells via a disulphide bridge between the substrates
and Cys78 in the hinge region of ISG15. While the ISG15 activating enzyme UBE1L is conjugated by ISG15 in the classical
way, we show that the ubiquitin conjugating enzyme Ubc13 can either be classically conjugated by ISG15 or can form a
disulphide bridge with ISG15 at the active site cysteine 87. The latter modification would interfere with its function as
ubiquitin conjugating enzyme. However, we found no evidence for an ISG15 modification of the dynamin-like GTPases MxA
and hGBP1. These findings indicate that the analysis of potential substrates for ISG15 conjugation must be performed with
great care to distinguish between the two types of modification since many assays such as immunoprecipitation or metal-
chelate affinity purification are performed with little or no reducing agent present.
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Introduction
Interferons (IFNs) play a key role in the defence against viral,
bacterial and protozoan infections [1]. The biological response to
IFNs requires binding of the IFN molecules to type-specific
receptors, which results in the activation of signalling pathways
and the transcriptional upregulation of hundreds of IFN-stimulat-
ed genes (ISGs). One of the most highly induced ISGs by type I
IFN (e.g. a and b) is ISG15 [2]. ISG15 is a critical molecule for the
response against several viral infections since ISG152/2 mice are
more sensitive to influenza A and influenza B viral infections and
also show an increased susceptibility to murine herpes virus and to
Sindbis virus [3]. The increased sensitivity of ISG15 knockout
mice to Sindbis virus infection could be rescued by expressing wild
type ISG15 [3]. Moreover, it has been shown that both,
conjugated ISG15 and the unconjugated form possess antiviral
activity [4–6].
ISG15 can also be secreted from human monocytes and
lymphocytes [7] to act as a cytokine by inducing the production of
IFN-b, proliferation of natural killer cells, neutrophil chemotaxis,
and dendritic cell maturation [2,8–10].
Initially, ISG15 has been identified as ubiquitin cross-reactive
protein (UCRP) in mouse tumor cells [11] and it shares an
amino acid sequence identity of about 30% with ubiquitin [12].
The overall structure of ISG15 consists of two ubiquitin-like
domains each adopting a b-grasp fold that is nearly identical to
ubiquitin. The two domains are connected by a six residue
extended linker, the hinge region, which comprises the amino
acids Asp76–Pro81 in human ISG15 including the water
accessible Cys78 [13]. As many other Ubls, human ISG15 is
expressed in an inactive precursor form. The maturation process
is a proteolytic cleavage of the C-terminus in order to expose a
di-glycine motif which is necessary for conjugation [12]. This
reaction can be catalysed by the ubiquitin-related protease
(UBP43) [14] but in vivo UBP43 seems to have also functions
which are unrelated to ISG15 [15].The classical pathway of
ISG15 conjugation (ISGylation) is initiated by the generation of a
thioester between the C-terminal glycine of ISG15 and a cysteine
of the activating E1 enzyme UBE1L. The activation energy is
supplied by ATP. ISG15 is then transferred to Cys85 in the
active site of the conjugating E2 enzyme UbcH8 (Ube2L6) via a
thioester bond. Together with the E2, an ISG15 E3 ligase (e.g.
Herc5, EFP or Hhari) transfers ISG15 to the e-amino group of a
lysine side chain in the substrate protein [16–20]. Besides ISG15
itself, also other components of the ISGylation cascade (UBE1L,
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As a result, the levels of ISG15 conjugates are tightly controlled
by IFN. In several studies, hundreds of target proteins for
ISGylation have been identified which are involved in diverse
cellular pathways [4,18,20,24–27]. Only some substrates were
found in all studies which may be attributed to the fact that
different cell lines were used [18,20,24–26]. Furthermore, some
studies used IFN-induced cells [20,24] while others transfected
the proteins of the ISG15 conjugation cascade [18] or both [25].
The function of ISG15 modification has only been assessed for
very few ISG15 substrates. One of them is Ubc13, which forms a
heterodimer with Mms2 [28]. This complex has ubiquitin-
conjugating activity and mediates the formation of K63-linked
polyubiquitin chains on proteins involved in DNA repair, NF-kB
signalling and mitosis [29–31]. Zou et al. have shown that
modification of Ubc13 by ISG15 at Lys92 suppresses its ability to
build a thioester bond with ubiquitin and thus Ubc13-mediated
ubiquitylation is impaired [32]. Consequently, modification of
Ubc13 by ISG15 has an indirect effect on different cellular
functions. A negative regulation by ISGylation has also been
reported for the oncogenic fusion protein of the promyelocytic
leukemia protein (PML) and the retinoic acid receptor a (RARa)
[33]. The authors reported that UBE1L mediated ISGylation of
the PML part in the PML/RARa protein is involved in its
proteasomal degradation. Consistent with this, depletion of the
ISG15 specific protease USP43 destabilized the PML/RARa
protein [34].One example of how ISG15 interferes with viral
replication is the modification of viral proteins such as NS1
(Non-structural protein 1) from influenza virus A, which is
ISGylated on Lys 41 [35]. ISG15 also serves as a negative
feedback regulator of interferon induction by modifying the IFN-
inducing protein RIG-I (Retinoic acid-inducible gene-I) [36].
ISG15 conjugation to RIG-I increases in the presence of a
proteasomal inhibitor, which may indicate a crosslink between
proteasomal degradation and ISGylation [36]. Other potential
ISG15 substrates with antiviral function include the dynamin-like
GTPases MxA (myxoma resistance protein 1) and hGBP1
(human guanylate binding protein 1) [25]. MxA confers
resistance to influenza A virus and vesicular stomatitis virus
[37,38]. Zhao et al. have shown that MxA can be multiply
modified by ISG15, but the function of this modification
remained unknown [25]. Recently, Durfee and colleagues have
found that newly synthesized proteins are predominant targets
for ISGylation and that the ISG15 ligase Herc5 is associated with
polyribosomes [39]. They propose an alternative model for the
antiviral function of ISGylation by blocking the regular assembly
of viral capsids.
We were interested to analyse the modification of several ISG15
substrates in more detail by applying a similar transfection and
purification strategy as the above mentioned studies. In the course
of our experiments, however, we observed that the levels of ISG15
modified proteins were increased in the presence of low amounts
of reducing agents which are required for metal-chelate affinity
purifications and immunoprecipitations. We demonstrated that
this ‘atypical’ reducing agent sensitive ISG15 modification exists
also in living cells and may be functionally relevant. Further
investigations of the mechanism of ISG15 modification by
mutational analysis and miRNA-mediated knock-down revealed
that Cys78 in the hinge region of ISG15 is responsible for the
atypical ISG15 modification and that Ubc13 can be modified via
this cysteine residue.
Results
ISG15 Modification can be Decreased by Reducing
Agents
In order to analyse the modification of several IFN-induced
ISG15 substrates, we established a protocol to isolate ISG15
modified proteins after IFN-b induction of HeLa cells transfected
with RGS-His- or His-S-tagged maturated human ISG15 (residues
1–157) by metal-chelate affinity purification in analogy to the
study by Zhao et al. [25]. Under these conditions, we expect that
also considerable amounts of the presumed ISG15 processing and
deconjugating enzyme UBP43, the activating and conjugating
proteins UBE1L and UbcH8 and also several ligating enzymes
such as Herc5, Hhari and EFP are expressed. In order to optimize
the purification, we compared different metal-chelate matrices
which work in the presence of different concentrations of reducing
agents (DTT and 2-ME). When we analysed the amount of ISG15
modified proteins in the cell lysates and after metal-chelate
purification by Western blotting, we observed that ISG15
modification was decreased with increasing amounts of reducing
agent while free ISG15 became more abundant (data not shown).
This effect became much more prominent, when the SDS-PAGE
was performed with a loading buffer without reducing agent
(Figure 1A). To avoid the formation of SDS resistant aggregates, it
was important not boil the samples without reducing agent. A
critical question arising from these results was if this type of ISG15
modification existed also in living cells or whether it was a mere
artefact caused during cell lysis in buffers containing low amounts
of reducing agents. Therefore IFN-induced HeLa cells were
treated with N-ethylmaleimide (NEM) which is cell-permeable and
irreversibly blocks free thiol groups [40]. NEM was added either
30 min before or during lysis or both and the levels of ISG15
modified proteins in the absence and presence of reducing agent
were compared and analysed (Figure 1B). Addition of NEM led
only to a slight reduction of ISG15 modification. In all cases the
levels of ISG15 modification could be decreased by the addition of
reducing agent while the levels of free ISG15 increased showing
that the reduction sensitive modification had already existed in
living cells. The reduction of ISG15 conjugates was readily
detectable along the length of the SDS-PAGE from above 43 kDa
indicating that many ISG15 substrates are affected. The quanti-
fication of the entire ISG15 signal in this region and of free ISG15
running approximately at 15 kDa indicated that about 40% of the
total ISG15 modifications are sensitive to reducing agents
(Figure 1C). Similar results were obtained with MMTS
(Figure 1D) another thiol-blocking reagent [41]. Addition of
hydroxylamine at neutral pH to cell lysates had no effect on ISG15
conjugates in the absence of 2-ME. This indicates that the
reducing agent sensitive ISG15 conjugates are linked by disulphide
bridges and not thioesters (Figure S1). A time resolved analysis
revealed that ISG15 conjugates occur already 6–12 h after IFN
induction but until 24 h post induction they are mainly composed
of reduction sensitive conjugates (Figure 1E).
Cys78 of ISG15 Plays a Role in Modification
Protein modifications which are sensitive to reducing agents
include disulphide bridges and thioesters. While the amount of
disulphidebridgeswithinthecytosolisusuallylowduetothepositive
redox potential of the cytosol [42], thioesters occur as high energy
compounds including the activated states of ubiquitin-like proteins
with their activating E1 and conjugating E2 enzymes and with
HECT-type E3 ligases. In these cases, specific cysteine residues in
theactivesitesoftheE1,E2orE3enzymesarelinkedtothecarboxyl
groupoftheC-terminalglycineresidueintheUbl.Theonlycysteine
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between the two ubiquitin-like domains. This cysteine is highly
conservedinothermammalianISG15proteinswiththeexceptionof
porcine ISG15 (Figure 2). Moreover, Cys78 in ISG15 has been
found to be highly reactive leading to dimerization of the protein or
to the modification by nitric oxide (NO) [43,44].
Figure 1. Decrease of ISG15 conjugates by reducing agents. (A) HeLa cells were transiently transfected with pTriEx2-His-S-ISG15. 24 h post-
transfection, the cells were induced with IFN-b (1,000 units/ml). Purifications of ISG15 modified proteins were carried out under denaturating
conditions without 2-ME. Eluates were equally split and treated with or without 2-ME before SDS-PAGE. (B) The IFN-b induced HeLa cells were treated
with or without 40 mM NEM (NEM pre-lysis) for 30 min at 37uC. The cells were lysed with or without 20 mM NEM (NEM post-lysis). Equal loading of
total protein is indicated by immunoblotting against alpha-tubulin. (C) The presence of reducing agent leads to a decrease of ISG15 modification and
an increase of free ISG15. All data were derived from three independent experiments. Statistical analyses were conducted using SigmaPlot10 (Systat
Software Inc) software and values were presented as mean 6 SD. Significant differences between the groups were analysed by One Way ANOVA
followed by Student-Newman-Keuls Method. A value of P,0.05 was accepted as an indication of statistical significance. (D) IFN-b induced HeLa cells
were treated with or without NEM (pre- and post-lysis as in Figure 1B) and 1 mM MMTS (pre- and post-lysis). PVDF membrane was stripped and
immunodecorated with anti-actin antibody (low panel). (E) The time course of ISG15 conjugation was studied after induction of HeLa cells with IFN-b
for indicated times treated with or without NEM as in Figure 1D.
doi:10.1371/journal.pone.0038294.g001
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modification, we generated mutants of maturated human ISG15
where Cys78 was either exchanged to glycine (ISG15-C78G), or to
serine (ISG15-C78S) or where the C-terminal Gly-Gly sequence
was deleted (ISG15-DGG) as well as a double mutant containing
both mutations (ISG15-C78S/DGG). The levels of ISG15
modification of these mutants and ISG15-WT were analysed by
Western blotting after co-transfection with Flag-tagged UBE1L
and HA-tagged UbcH8 (Figure 3A) in non IFN-induced cells.
ISG15-WT modification was increased by co-transfection with
UBE1L and even further with UBE1L and UbcH8 but was
sensitive to reducing agent. ISG15-C78G alone or with UBE1L
displayed almost no ISG15 modification but high levels in the
presence of both UBE1L and UbcH8. Under these conditions,
ISG15 modifications in the low (26–43 kDa) and in the high
(. 130 kDa) but not in the medium (43–130 kDa) molecular
weight (MW) range were insensitive to reducing agents. ISG15-
DGG mainly displayed modified proteins in the medium range
(43–130 kDa) which were slightly increased by co-expression of
UBE1L and UbcH8 but which were completely lost in the
presence of reducing agents. Similar results were obtained by
Co
2+2chelate affinity purification of ISG15 modified proteins
without 2-ME which also showed that no ISG15 modification
occurred in the presence of the ISG15-C78S/DGG double mutant
(Figure 3B). Anti-FLAG Western blotting revealed that the high
MW bands of ISG15-WT, ISG15-C78S and ISG15-C78G are
linked to UBE1L. Since the SDS-PAGE was performed without
reducing agent, these high MW bands could represent ISG15
intermediates linked via thioester to UBE1L. We further
investigated the role of Cys78 in the context of the modification
of UBE1L. Immunoprecipitation of Flag-tagged UBE1L with
subsequent SDS-PAGE under reducing conditions confirmed that
UBE1L can be ISGylated by ISG15-WT and ISG15-C78S at
multiple sites but none of the mutants lacking the double glycine
were able to modify UBE1L, identifying UBE1L as a classically
modified ISG15 substrate (Figure 3C).
Ubc13 can be Modified by ISG15 via an Isopeptide Bond
and a Disulphide Bond
Next we were interested to see whether other known ISG15
substrates are in fact not linked via an isopeptide bond but via the
reducing agent sensitive linkage to Cys78. To this end, we
transiently transfected Ubc13 which has been described as ISG15
substrate in the literature [24,45] together with wild type or
mutants of ISG15 and with UBE1L, UbcH8 and Herc5. As before
for UBE1L we checked for ISG15 modification in the presence of
reducing agent in total lysates and after immunoprecipitation of
the substrate (Figure 4). After immunoprecipitations, Ubc13,
which has a molecular weight of 17 kDa, ran at a major band at
17 kDa, two minor bands around 26 kDa and another weak band
above 34 kDa. The bands at 26 kDa represent Cys-linked dimers
of Ubc13 and monoubiquitylated Ubc13. Western blotting against
ISG15 revealed that band above 34 kDa corresponds to ISG15
modification, since it was absent in the case of the DGG/C78S
mutant and enhanced by transfection of the ISG15 ligase Herc5.
The ISG15 conjugation to Ubc13 was highly reduced by the
mutation of Cys87 in Ubc13 (see also further below) and
completely abolished by mutation of the previously published
ISGylation site K92.
To examine whether ISG15 can be also linked via Cys78 to
endogenous Ubc13, we performed a pull-down of ISG15
conjugates on Talon matrices with and without 2-ME (Figure 5).
Therefore, HeLa cells were transiently transfected with His-S-
ISG15 (wild type and mutants), Flag-UBE1L and HA-UbcH8. As
before, we observed a strong effect of reducing agent on the total
amount of ISG15 modifications, which was diminished in the case
Figure 2. Amino acid alignment of ISG15 proteins from different vertebrate species with human di-ubiquitin. The potential
functionally important sites are highlighted. The C-terminal site including the double glycine motif for the conjugation to substrates is marked in
bold, cysteine residues are indicated in bold and italics and the conserved cysteine residues in hinge region are shaded in grey. Sequence analysis
was performed using ClustalW.
doi:10.1371/journal.pone.0038294.g002
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the formation of reduction sensitive ISG15 modifications. A stable
isopeptide linkage to Ubc13 could be observed with the ISG15
Cys78 mutant and thus also confirmed previous results from others
[32,45]. Furthermore, endogenous Ubc13 is able to covalently
interact with ISG15-WT as well as the C78S and DGG mutants
without 2-ME (Figure 5). However, in the presence of 2-ME, the
modification of Ubc13 with ISG15-WT is less pronounced and
completely lost with the DGG mutant, indicating that at least parts
of the interaction observed under non-reducing conditions is
Figure 3. Mutational analysis of ISG15. (A) HeLa cells were transiently transfected with pCMV2a-Flag-UBE1L, pCMVb-HA-UbcH8 and pCMVb-
MRGS-His-ISG15 WT or different mutants. 24 h post-transfection, the cells were collected and lysed with or without 2-ME. (B) Isolation of ISG15
conjugates by metal-chelate pull-down. HeLa cells were transiently transfected with pCMV2a-Flag-UBE1L and pCMVb-MRGS-His-ISG15 WT and
different mutants. 24 h post-transfection the cells were collected and lysed without 2-ME. The metal-chelate pull-downs and the SDS-PAGE were
carried out under denaturing conditions without 2-ME. The asterisk indicates an unspecific band. (C) Analysis of ISG15 modification of UBE1L by anti-
FLAG pull-down. HeLa cells were transiently transfected with pCMV2a-Flag-UBE1L, pCMVb-HA-UbcH8 and pCMVb-MRGS-His-ISG15 WT and different
mutants. 24 h post-transfection, the cells were collected and lysed. Flag-UBE1L was immunoprecipitated with anti-FLAG M2 Sepharose as described.
SDS-PAGE was carried out in presence of 2-ME. Equal protein loading was verified by immunoblotting against alpha-tubulin.
doi:10.1371/journal.pone.0038294.g003
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of ISG15 nor a stable isopeptide linkage but instead occurs via
Cys78 in ISG15.
MxA and PML are not Modified by ISG15
Similar to our previous experiments, we tried to investigate the
ISG15 modification of MxA and also of the human guanylate-
binding protein 1 (hGBP1) which have been described in the
literature [25–26,39]. In cell lysates of IFN-induced cells we
couldn’t detect any slower migrating bands for hGBP1, while we
observed several additional bands in Western blots against MxA in
the range between 95–130 kDa. Those bands vanished with
increasing concentrations of reducing agents in the SDS-loading
buffer (Figure 6A). After immunoprecipitations of MxA these
bands were not observed in the presence of 2-ME (Figure 6B, C),
so that we assumed MxA is atypically modified by ISG15. The co-
expression of WT or mutant ISG15, even with Herc5 had also no
influence on the appearance of these bands (Figure 6B, C). In cases
where these bands were detected, they displayed variable
intensities between experiments and they were always sensitive
to reducing agents. Together with the previous experiments we
conclude that the higher MW bands of MxA are neither caused by
classical nor atypical ISG15 modification, but probably appear
due to running artefacts on SDS-PAGE with insufficient amounts
of reducing agent and boiling. We also found no evidence for an
ISG15 modification of the endogenous PML protein. In the same
experiment we were able to specifically isolate PML, which was
modified by the small ubiquitin-related modifier (SUMO) proteins
(Figure 6D) [46,47].
Downregulation of ISG15 Modification by miRNA
In order to confirm the different modes of ISG15 modification,
we used a system for the transient downregulation of ISG15 by
miRNA (Figure 7). As seen in Figure 7A, expression and excision
of the mRNA coding for GFP and the miRNA against ISG15
resulted in a significant depletion of ISG15 in IFN-b induced cells
in contrast to the expression of an mRNA coding for GFP and a
control miRNA. We also established stable cell lines expressing
these RNAs but in this setting, the expression of the miRNA was
not high enough to suppress the strong induction of ISG15 by
IFN-b (data not shown). Therefore we used the GFP expression to
enrich transfected cells by FACS for Western blotting. In these
cells, ISG15 expression was reduced to less than 25% compared to
the control cells expressing the control miRNA (Figure 7B). Co-
expression of the ISG15 knock-down construct with Ubc13 WT
resulted in a strong reduction of the band above 34 kDa
(Figure 7C). As shown before, this band and the presumed
Ubc13 dimer were absent when the C87G mutant of Ubc13 was
Figure 4. Different types of ISG15 modification of Ubc13. HeLa cells were transiently transfected with pCMVb-HA-Ubc13 WT, pCMVb-HA-
Ubc13 C87G mutant or pCMVb-HA-Ubc13 K92R mutant and other vectors as shown in the figure. 24 h post-transfection the cells were collected and
lysed. Anti-HA immunoprecipitations were performed as described. Immunoblotting against the S-tag shows the expression levels of both UBE1L and
UbcH8. SDS-PAGE was carried out in presence of 2-ME. The asterisk indicates monoubiquitylated Ubc13 and the hash dimers of Ubc13.
doi:10.1371/journal.pone.0038294.g004
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of UBE1L ISGylation (Figure 7C). Furthermore we applied the
miRNA approach to analyse the potential modification of MxA,
which is strongly induced by IFN-b. Thus we could investigate the
possible modification of transient transfected Flag-MxA (Figure 7C)
as well as endogenous MxA (Figure 7D). Again we found no
evidence for any kind of modification of MxA by ISG15.
Discussion
In several studies, many proteins have been identified as
substrates for ISGylation using proteomic approaches [24–26,48].
Interestingly, not all substrates were found in every study. This
could be explained by the use of different cell lines, different
transfection of the ISG15 machinery as well as different ways of
purifying ISG15 conjugates. Furthermore, only a small percentage
of each individual substrate has been found to be ISG15 modified
at any given time. We found that ISG15 modification of proteins is
partially sensitive to reducing agents and that these conjugates also
exist in living cells (Figure 1). The mutation of the single cysteine
(Cys78) and the C-terminal di-glycine motif in ISG15 as well as the
incubation of cell lysates with hydroxylamine showed that Cys78
forms disulphide bridges with other proteins. This residue is highly
conserved within mammalian ISG15 genes and located in the
hinge region between the two ubiquitin-like domains and has
previously been shown to be highly reactive [43,44].
We show that UBE1L, the E1 enzyme of ISG15, is a major
substrate for ISGylation itself (Figure 3B) [24,27].
Another ISG15 substrate that we analysed in more detail is
Ubc13. Previously, ISGylation at lysine 92 of Ubc13 had been
described to inhibit its function as ubiquitin conjugating enzyme
[32,45]. We found that Ubc13 can not only be modified by ISG15
via an isopeptide bond but it can also be modified via a disulphide
bond between Cys78 of ISG15 and the single Cys87 of Ubc13
(Figures 4, 5, 7).
While we were able to confirm the ISGylation of both,
Ubc13 and UBE1L, by transient downregulation of ISG15 with
a specific miRNA we could not see any effect on the previously
described substrate MxA (Figure 7). We also tried to isolate
ISG15 modified MxA protein. Despite the use of several
purification protocols, we could only observe additional bands of
MxA in the absence of reducing agent. These bands were never
positive for ISG15 in Western blotting nor were they reduced in
ISG15 knock-down cells. This led us to conclude that these
bands are caused by a SDS-PAGE artefact. Further, we also
found no evidence for an ISG15 modification of hGBP1
(Figure 6A) or PML (Figure 6D).
In summary we conclude, that a large proportion of the
ISG15 modifications in living cells are not attached to the
substrates via the di-glycine motif but via disulphide bridges
between the single cysteine in the hinge region of ISG15 and a
cysteine of the substrate. Thus, it may be difficult to distinguish
Figure 5. Different types of ISG15 modification of endogenous Ubc13. HeLa cells were transiently transfected with pCMVb-HA-Ubc13 WT
(A) or pCMVb-HA-Ubc13 C87G (B) mutant and other vectors as shown in the figure. 24 h post-transfection the cells were collected and lysed in
presence 2-ME. The metal-chelate pull-downs were carried out under denatured conditions with or without 2-ME. Immunoblotting against the S-tag
show the levels of ISG15. Equal loading of total protein was verified by anti alpha-tubulin immunoblotting.
doi:10.1371/journal.pone.0038294.g005
Atypical ISG15 Modification via Cysteine 78
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38294between these two types of modifications when immunoprecip-
itations or metal-chelate affinity purifications are applied to
isolate ISGylated proteins, because usually little or no reducing
agents are present. We show that mutagenesis of Cys78 and the
C-terminal di-glycine motif can be used to discriminate these two
possibilities. Furthermore, for a complete reduction of disulphide
Figure 6. No evidence for ISG15 modification of MxA, hGBP1 and PML. (A) HeLa cells were induced with IFN-b for 24 h. The cells were lysed
in urea buffer without reducing agent. Cellular lysates were equally aliquoted and 2-ME was added (loading to SDS-PAGE from left to right: 500 mM,
100 mM, 50 mM, 20 mM, 10 mM, 5 mM, 1 mM 2-ME, empty lane, 0 mM 2-ME) and blotted for MxA and hGBP1. (B) HeLa cells were transiently
transfected with pCMV2b-Flag-MxA and the components of the ISG15 conjugation machinery as indicated in the figure. 24 h post-transfection, the
cells were induced with IFN-b24 post-induction the cells were collected and lysed without 2-ME. Anti-FLAG immunoprecipitations were performed
without 2-ME. Eluates were equally split and treated with or without 2-ME before SDS-PAGE (C) HeLa cells were transiently transfected with pCMVb-
HA-MxA and components of the ISG15 conjugation machinery as indicated in the figure. 24 h post-transfection, the cells were collected and lysed
without 2-ME. Anti-HA immunoprecipitations were performed. Eluates were equally split and treated with or without 2-ME before SDS-PAGE. (D)
HeLa cells were transiently transfected with either pCMVb-MRGS-His-ISG15 or pCDNA4/TO/N-MRGS-His-SUMO2. 24 h post-transfection, the cells were
induced with IFN-b (1,000 units/ml). Purifications of ISG15 or SUMO2 modified proteins were carried out under denaturating conditions without 2-
ME. Eluates were equally split and treated with or without 2-ME before SDS-PAGE.
doi:10.1371/journal.pone.0038294.g006
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SDS-loading buffer with freshly added and sufficient amounts of
reducing agent.
The physiological relevance of the Cys78-dependent, atypical
form of ISG15 modification remains unclear. For Cys87 in Ubc13
which is located in the active centre and is used to build thioesters
Figure 7. Substrate analysis after downregulation of ISG15. HeLa cells were transiently transfected with ISG15 or control miRNA vectors in
which the miRNA is coded from the 39-UTR of GFP. 12 h post-transfection the cells were induced with IFN-b for another 12 h. (A) After a total of 24 h
post-transfection, cells were fixed and subjected to immunofluorescent staining with rabbit polyclonal ISG15 antibody and secondary Alexa Fluor 647
donkey-anti-rabbit antibody (red) and compared to the GFP signal (green). (B) GFP-positive cells were FACS sorted, lysed in urea buffer and analysed
for ISG15 downregulation by Western blotting with reducing agent. (C) HeLa cells from the experiment in (B) were additionally co-transfected with
pCMV2a-Flag-UBE1L, pCMV2b-Flag-MxA, pCMVb-HA-Ubc13 WT or C87G mutant or and analysed for substrate specific ISGylation by Western blotting
in presence of reducing agent. Equal loading of total protein was verified by anti-alpha-tubulin immunoblotting. (D) FACS sorted GFP-positive HeLa
cells from the experiment in (B) were lysed with and without 2-ME and analysed by Western blotting against endogenous MxA.
doi:10.1371/journal.pone.0038294.g007
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by ISG15 would as well inhibit the function of Ubc13 by
preventing the loading with ubiquitin. We cannot exclude that
cysteine-linked ISG15 modifications just represents an unspecific
side reaction, but in principle it could also be regulated by the
cellular redox potential or the concentration of reactive oxygen
species due to cellular stresses. ISG15 Cys78 has already been
shown to be highly reactive and is involved in dimerization which
can be prevented by nitrosylation [43]. Recently, is has been
shown that the classical ISGylation involving the isopeptide
linkage formation targets mainly freshly synthesized proteins due
to an association of the E3 ligase Herc5 with the ribosome [39].
The authors of this study concluded that ISGylation of only a
proportion of viral proteins would impair the assembly of viral
particles. This mechanism could also explain how ISG15
modification could act despite the substoichiometric modification
of the substrates. Other studies have shown that the accumulation
of ISGylated proteins is slow despite the rapid induction of ISG15
by IFN-b induction [21,49] since the synthesis of the E1, E2 and
E3 enzymes is delayed. Consistent with this, we found after
induction of cells with IFN-b that the reduction sensitive
conjugates occur several hours earlier than the insensitive
ISGylated proteins (Figure 1E). Furthermore, also unconjugated
ISG15 has been shown to have antiviral activity [4,5]. Therefore
another attractive hypothesis would be that the modification via
the cysteine of ISG15 allows it to broaden its target scope and to
achieve a similar amount of modified proteins before the synthesis
of the ISGylation enzymes has been upregulated.
Materials and Methods
Plasmids and Antibodies
The cDNAs encoding for ISG15 (IMAGE ID IR-
AUp969E1149D, GenBank identification number (GI):
BC009507), UbcH8 (UBE2H) (IMAGE ID IRAUp969G0731D,
GI: BC006277), UBE1L (UBA7) (IMAGE ID IRAUp969H0433D,
GI: BC006378), Ubc13 (IMAGE ID IRATp970B041D, GI:
BC003365) and MxA (IMAGE ID IRATp970B1055D6, GI:
BC032602) were purchased from ImaGenes (now Source BioSci-
ence). The pCDNA-Flag-Herc5 construct was kindly provided by
K. Hochrainer [50]. The pCDNA4/TO/RGSHis6-SUMO2 has
been previously described [47].
In order to generate expression vectors, ORFs were amplified
by PCR and subcloned into the pTriEx-2 vector (Novagen),
pCMV vectors (Stratagene) or modified pCMV2b vectors where
the Flag-tag was replaced by either a double HA- or RGS-His-tag.
ISG15 C78G, C78S and DGG as well as Ubc13 C87G mutations
were obtained by site-directed mutagenesis using the Quik-
Change Site Directed Mutagenesis kit (Stratagene).
Immunoblotting was performed with the following antibodies:
mouse monoclonal anti-a-tubulin, clone DM1A (Sigma-Aldrich),
rat monoclonal anti-HA, clone 3F10 (Roche), mouse monoclonal
anti-FLAG M2 (Sigma-Aldrich), mouse monoclonal anti-penta-
His (Qiagen), mouse monoclonal anti-RGS-His (Qiagen), mouse
monoclonal anti-S-tag (Novagen), rabbit polyclonal anti-PML
(Bethyl Laboratories) and rabbit polyclonal anti-ISG15 generated
using recombinant ISG15 as antigen as described below. Mouse
monoclonal anti-MxA (M143) was kindly provided by O. Haller
and G. Kochs (University of Freiburg) [51]. Rat monoclonal anti-
hGBP1 was kindly provided by M. Sturzl [52].
Cell Culture and Transfection
HeLa B cells (ECACC # 85060701) were cultured in
Dulbecco’s modified Eagle’s medium (Gibco) supplemented with
10% heat-inactivated calf serum (Sigma-Aldrich), penicillin
(100 units/ml) (Gibco), streptomycin (100 mg/ml) and Non-
Essential Amino Acids Solution 10 mM (100x) (Gibco) at 37uC
with 5% CO2 in a humidified incubator. Cells were transiently
transfected with GeneJuice (Novagen) according to the manufac-
turer’s instructions. For co-transfections, the total plasmid amount
for each transfection was normalized by the addition of
appropriate amount of empty vectors. For cytokine stimulation,
1,000 units/ml of human IFN-b (PeproTech) was used.
Metal-chelate Purification of ISG15 Conjugates
Purifications of ISG15 conjugates were performed with or
without reducing agent (DTT or 2-ME). In both cases, purification
was carried out under strong denaturing conditions, which
decreases unspecific binding to metal-chelate matrices. Cultured
HeLa cells (4610
6) were transiently transfected with His-tagged
ISG15 (pCMVb-MRGS-His-ISG15, pTriEx2-His-S-ISG15 wild
type or its mutants) and other plasmids (pTriEx2-His-S-UBE1L,
pCMV2a-Flag-UBE1L, pCMVb-HA-UbcH8, pTriEx2-His-S-
UbcH8, pCMV2b-Flag-MxA, pCMVb-HA-MxA, pCMVb-HA-
Ubc13, pCMVb-HA-Ubc13 C87G), in conformity with the
experiment. 24 h post-transfection the cells were induced (if
necessary) with IFN-b (1,000 units/ml) for 24 h. Before lysis, cells
were rinsed twice with ice-cold PBS and cells were scratched with
a cell scraper in 5 ml ice-cold PBS. The cell suspension was
pelleted by centrifugation with low speed (3006g) for 5 min. PBS
was aspirated and 600 ml of urea buffer (50 mM Tris-HCl,
pH 8.0, 8 M urea, 5 mM imidazole, 1% Triton X-100 (w/V),
150 mM NaCl, 1% glycerol (w/V), with or without 5 mM 2-ME,
20 mM NEM, 25 mg/ml of leupeptin, aprotinin and pepstatin)
was added for resuspension of the cellular pellet. DNA was
removed by sonication. Cellular debris was pelleted by centrifu-
gation at 16,0006g for 10 min at 4uC. The clarified cellular lysate
was added to 50 ml TALON metal affinity resin (Clontech) pre-
equilibrated with urea buffer and incubated for 2 hours on a
rotation platform at 4uC. Afterwards, the resin was washed 5 times
with urea buffer, 3 times with Washing buffer (the same as urea
buffer but with 10 mM imidazole, pH 6.0). Finally, the resin was
transferred to centrifuge filter systems Mini (Roth) and centrifuged
with 2,0006g for 30 s at 4uC. The elution of ISG15 conjugates
was performed with 26SDS sample buffer containing 4 M urea,
50 mM EDTA, 750 mM imidazole and 500 mM 2-ME or not.
Transient Downregulation of ISG15 by miRNA
The miRNA oligomers (ISG15 miRNA:
TGCTGCTCACTTGCTGCTTCAGG
TGGGTTTTGGCCACTGACTGACCCACCTGACAG-
CAAGTGAG; control miRNA: TGCTGAAATCGCT-
GATTTGTGTAGTCGTTTTGGCCACTGACTGACGAC-
TACACATCAGCGATTT) for the transient downregulation of
ISG15 were purchased from Invitrogen and cloned following the
BLOCK-IT Pol II miR RNAi Expression Vector Kit with
EmGFP manual. The advantage of this system is the easy
detectable selective marker GFP, which is coded within the same
mRNA in an open reading frame in front of the miRNA. This
primary RNA will be cleaved by the Drosha complex to yield the
GFP mRNA and the ISG15 or control miRNA. Therefore, cells
which are positive for a GFP signal can be easily analysed by flow
cytometry or immunofluorescence. For this purpose, HeLa cells
were transiently transfected with control miRNA or ISG15
miRNA vectors. 12 h post-transfection, the cells were induced
with IFN-b (1,000 U/ml) for another 12 h. Then, the cells were
trypsinized to yield a proper cell suspension and analysed by a
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percentage of sorted green cells was $ 70% for each experiment.
Fluorescence Microscopy
For fluorescence microscopy, cells were grown on cover slips,
transfected and IFN- induced as described above. Cells were fixed
in PBS, 3% (w/V) paraformaldehyde, permeabilized with PBS,
0.2% Saponin (w/V, Roth) and blocked with PBS 0.2% Saponin
(w/V), 3% BSA (w/V, Fraction V, protease free; Roth). Primary
rabbit polyclonal ISG15 and secondary Alexa-labeled (Alexa Fluor
647 donkey-anti-rabbit IgG, Molecular Probes, Invitrogen)
antibodies were applied in blocking buffer. Cover slips were
embedded in ProLong Gold antifade (Invitrogen) and examined
using a Zeiss Axioplan2 fluorescence microscope.
Western Blotting and Immunoprecipitations
For Western blotting, cells were lysed in urea buffer (50 mM
Tris-HCl, pH 8.0, 8 M urea, 1% Triton X-100, 150 mM NaCl,
1% glycerol, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mg/1 ml
pepstatin). Cell lysates were mixed in a 5: 1 ratio with loading
buffer (250 mM Tris-HCl, pH 8.0, 25% (w/V) glycerol, 7.5% (w/
V) SDS, 0.25 mg/ml bromphenol blue) without or with 500 mM
2-ME. Protein samples were then resolved on 10% or 12% SDS-
PAGE, transferred onto an Immobilon-P PVDF membrane
(Millipore) and analysed by respective antibody staining as
indicated. The quantification of Western blots was performed
with Photoshop CS3 (Adobe Systems, San Jose, CA).
For immunoprecipitations, the indicated antibodies were
covalently bound to protein A-agarose beads (GE Healthcare)
using dimethyl pimelimidate, (DMP) (Merck KGaA) as cross
linker. Alternatively, mouse anti-FLAG M2 beads (Sigma-Aldrich)
or rat anti-HA beads (clone 3F10) (Roche) were used when
indicated. Equal amounts of IFN-b treated and/or transfected
cells were lysed in RIPA (radioimmunoprecipitation assay) buffer:
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100 (w/
V), 0.1% SDS (w/V), 0.5% sodium deoxycholate, 40 mM NEM,
25 mg/ml of leupeptin, aprotinin and pepstatin. Cellular debris
was removed by centrifugation at 12,0006g. The supernatant was
diluted 1:10 with PBS and incubated for 4–5 h with protein A-
sepharose-coupled antibodies. Immunoprecipitates were eluted
from beads with elution buffer (200 mM Tris-HCl, pH 9.0 and
1% SDS) and analysed by Western blotting with the indicated
antibodies.
Production of Polyclonal Rabbit Antibodies against
Recombinant ISG15
Rabbit immunization and serum collection was performed at
BioGenes using purified human ISG15 (see below). The antiserum
with the best reactivity toward ISG15 was harvested, aliquoted
and stored at 280uC until further use.
Expression and Purification of Recombinant ISG15
E. coli BL21 (DE3) containing a plasmid (pTriEx-2) with the
gene coding for His-S-tagged ISG15 protein were grown in LB
medium at 37uC up to mid-log phase (OD about 0.7 at 600 nm).
At this point, expression was induced by addition of 100 mM
IPTG at 30uC for 5 h. The cells were harvested and resuspended
in 50 mM Tris–HCl, pH 6.5, 5 mM CoCl2, 2 mM 2-ME, 10 mM
imidazole, 150 mM NaCl, EDTA-free protease inhibitor cocktail
(Roche), and lysed by sonication. Cellular debris was removed by
centrifugation (40,0006g) for 40 min. The clarified supernatant
was applied to Q-Sepharose column pre-equilibrated with lysis
buffer. The flow through from Q-Sepharose was applied to Co
2+-
IMAC column pre-equilibrated in the same buffer. For elution,
an imidazole gradient from 10 mM to 500 mM was applied over
3 column volumes. The eluted fractions containing His-S-ISG15
were collected and applied to Superdex 75 equilibrated with
50 mM Tris–HCl, pH 6.5, 2 mM 2-ME and 150 mM NaCl. In
order to remove the tag from His-S-ISG15, the protein
containing fractions from gel filtration were collected and
subjected to limited proteolysis by thrombin. Finally, the protein
solution was applied again to Superdex 75 pre-equilibrated with
10 mM sodium phosphate, pH 6.5 and 150 mM NaCl. The
fractions corresponding to monomeric untagged ISG15 were
collected and analysed by SDS-PAGE.
Supporting Information
Figure S1 No decrease of ISG15 conjugates by hydrox-
ylamine. IFN-b induced HeLa cells were treated with or without
NEM (pre- and post-lysis as in Figure 1B) and 0.2 M hydroxyl-
amine (post-lysis). PVDF membrane was stripped and immuno-
decorated with anti-actin antibody (low panel).
(TIF)
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